IDEAS home Printed from https://ideas.repec.org/a/aad/iseicj/v4y2016i0p740-743.html
   My bibliography  Save this article

New Compound N1,N1′-(2′′-Bromo-2′′-Chloroethenyl)-Bis-(5-Fluorouracil) As The Active Antitumor Agent For Sarcoma 180

Author

Listed:
  • Elena Welchinska

    (National Medical University)

  • Valeriia Vilchynska

    (National Medical University)

Abstract

The problem of how to treat malignant tumors and the search for effective low-toxic anticancer drugs are among the most important in modern medicine and other chemical and biological sciences, including pharmaceutical chemistry. The arsenal of anticancer drugs occupies a prominent position as medications related to heterocyclic systems (cancer of the digestive system and other areas). In this regard, further development towards new derivatives of purine and pyrimidine series are of significant scientific interest and justify the relevance, novelty, and scientific practical significance of this study. Synthesis of 5-fluorouracil bis-derivative was performed with a halogen-containing pharmacophore group to compose a molecule that was studied for its physical, chemical, and biological properties. Synthesis of 5-fluorouracil bis-derivative is a typical example of substitution reactions with a heteroatom of the uracil molecule (N1) as the second component in the reaction involving halothane, a known inhaled anesthetic. The reaction was carried out in a solvent system of benzene-dimethylformamide-diethyl ether, under conditions of phase transfer catalysis with dibenzo-18-crown-6 (DB 18C6) complex (alkaline medium), by heating (14 h), followed by purification, and drying of the products. The structure of the synthesized compound was confirmed by elemental analysis, infrared, and proton nuclear magnetic resonance (1H NMR) spectroscopy. By varying the reaction conditions, a synthesized compound of high purity was obtained with increased practical output of up to 50%. The toxicity and antitumor activity of the synthesized compound were investigated. The new substance, 5-fluorouracil bis-derivative, was found to have high antitumor activity, reducing the Sarcoma 180 tumor by 51.7% (activity criterion > 50%). This suggests the synthesized compound is suitable as a physiologically active treatment and its further study as a potential vehicle for anti-tumor treatment in patients is recommended.

Suggested Citation

  • Elena Welchinska & Valeriia Vilchynska, 2016. "New Compound N1,N1′-(2′′-Bromo-2′′-Chloroethenyl)-Bis-(5-Fluorouracil) As The Active Antitumor Agent For Sarcoma 180," CBU International Conference Proceedings, ISE Research Institute, vol. 4(0), pages 740-743, September.
  • Handle: RePEc:aad:iseicj:v:4:y:2016:i:0:p:740-743
    DOI: 10.12955/cbup.v4.842
    as

    Download full text from publisher

    File URL: https://ojs.journals.cz/index.php/CBUIC/article/view/842/934
    Download Restriction: no

    File URL: https://libkey.io/10.12955/cbup.v4.842?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:aad:iseicj:v:4:y:2016:i:0:p:740-743. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Petr Hájek (email available below). General contact details of provider: https://ojs.journals.cz/index.php/CBUIC .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.